Plasma and cerebrospinal fluid pharmacokinetics of intravenous oxaliplatin, cisplatin, and carboplatin in nonhuman primates

Clinical Cancer Research

Volumn 11, Issue 4, 2005, Pages 1669-1674

  Jacobs, Shana S ^a   Fox, Elizabeth ^a   Dennie, Christopher ^a   Morgan, Lindsey B ^a   McCully, Cynthia L ^a   Balis, Frank M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DRUG METABOLITE; OXALIPLATIN; PLATINUM DERIVATIVE;

ADOLESCENT; ANALYTIC METHOD; AREA UNDER THE CURVE; ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; COMPARTMENT MODEL; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DISPOSITION; DRUG HALF LIFE; DRUG PENETRATION; FIRST ORDER RATE CONSTANT; INTRAVENOUS DRUG ADMINISTRATION; LINEAR TRAPEZOIDAL METHOD; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PHARMACOKINETICS; PLASMA; PRIMATE; PRIORITY JOURNAL; RHESUS MONKEY; ULTRAFILTRATION;

ANIMALS; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; CARBOPLATIN; CISPLATIN; INFUSIONS, INTRAVENOUS; MACACA MULATTA; MALE; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; ORGANOPLATINUM COMPOUNDS;

EID: 14644394281     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-1807     Document Type: Article

References (22)

1. Huncharek M, Kupelnick B, Bishop D. Platinum analogues in the treatment of recurrent high grade astrocytoma. Cancer Treat Rev 1998;24:307-16.
2. Raymond E, Faivre S, Woynarowski JM, Chaney SG. Oxaliplatin: mechanism of action and antineoplastic activity. Semin Oncol 1998;25:4-12.
3. Rixe O, Ortuzar W, Alvarez M, et al. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem Pharmacol 1996;52:1855-65.
4. Ibrahim A, Hirschfeld S, Cohen MH, Griebel DJ, Williams GA, Pazdur R. FDA drug approval summaries: oxaliplatin. Oncologist 2004;9:8-12.
5. Culy CR, Clemett D, Wiseman LR. Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies. Drugs 2000;60:895-924.
6. Mani S, Graham M, Bregman DB, Ivy P, Chaney S. Oxaliplatin: a review of evolving concepts. Cancer Invest 2002;20:246-63.
7. Daley-Yates PT, McBrien DC. Cisplatin metabolites in plasma, a study of their pharmacokinetics and importance in the nephrotoxic and antitumour activity of cisplatin. Biochem Pharmacol 1984;33:3063-70.
8. Brunner V, Houyau P, Chatelut E, Roche H, Canal P. Cerebrospinal fluid concentrations of carboplatin in a patient without blood-brain barrier disruption. Cancer Chemother Pharmacol 1995;35:352-3.
9. Vlasveld LT, Beynen JH, Boogerd W, Bokkel Huinink WWT, Rodenhuis S. Complete remission of brain metastases of ovarian cancer following high-dose carboplatin: a case-report and pharmacokinetic study. Cancer Chemother Pharmacol 1990;25:382-3.
10. Riccardi R, Riccardi A, Di Rocco C, et al. Cerebrospinal fluid pharmacokinetics of carboplatin in children with brain tumors. Cancer Chemother Pharmacol 1992;30:21-4.
11. Armond JP, Macquet JP, LeRoy AF. Cerebrospinal fluid-platinum kinetics of cisplatin in man. Cancer Treat Rep 1983;67:1035-7.
12. Laurell G, Anderson A, Engstrom B, Ehrsson H. Distribution of cisplatin in perilymph and cerebrospinal fluid after intravenous administration in the guinea pig. Cancer Chemother Pharmacol 1995;36:83-6.
13. DeGregorio M, Wilbur B, King O, et al. Peak cerebrospinal fluid platinum levels in a patient with ependymoma: evaluation of two different methods of cisplatin administration. Cancer Treat Rep 1986;70:1437-8.
14. Guide for the care and use of laboratory animals, Department of Health and Welfare Publication (NIH). Washington (DC): U.S. Government Printing Office; 1996.
15. McCully C, Balis F, Bacher J, Phillips J, Poplack D. A rhesus monkey model for continuous infusion of drugs into cerebrospinal fluid. J Anim Sci 1990;40:520-5.
16. Services USdoHaH, Administration FaD, Research cfDEa, Medicine CfV. Guidance for industry: bioanalytical method validation. Rockville MD: 2001.
17. Graham MA, Lockwood GF, Greenslade D, Brienza S, Bayssas M, Gamelin E. Clinical pharmacokinetics of oxaliplatin: a critical review. Clin Cancer Res 2000;6:1205-18.
18. Gormley PE, Gangji D, Wood JH, Poplack DG. Pharmacokinetic study of cerebrospinal fluid penetration of cis-diamminedichloroplatinum (II). Cancer Chemother Pharmacol 1981;5:257-60.
19. Allen J, Graham M, Firth JW, et al. Biotransformation and pharmacokinetic analysis of oxaliplatin in patients with advanced gastrointestinal cancer. Proc AACR 1998;39:159.
20. O'Dwyer PJ, Stevenson JP, Johnson SW. Clinical pharmacokinetics and administration of established platinum drugs. Drugs 2000;59 Suppl 4:19-27.
21. Takimoto CH, Remick SC, Sharma S, et al. Administration of oxaliplatin to patients with renal dysfunction: a preliminary report of the national cancer institute organ dysfunction working group. Semin Oncol 2003;30:20-5.
22. Calvert H, Judson I, van der Vigh WJF. platinum complexes in cancer medicine: pharmacokinetics and pharmacodynamics in relation to toxicity and therapeutic activity. In: Workman P, Graham MA, editors. Cancer surveys, vol 17: pharmacokinetics and cancer chemotherapy. Vol 17. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press; 1993. p. 189-217.